Literature DB >> 15531405

Identification of separable cognitive factors in schizophrenia.

Keith H Nuechterlein1, Deanna M Barch, James M Gold, Terry E Goldberg, Michael F Green, Robert K Heaton.   

Abstract

One of the primary goals in the NIMH initiative to encourage development of new interventions for cognitive deficits in schizophrenia, Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS), has been to develop a reliable and valid consensus cognitive battery for use in clinical trials. Absence of such a battery has hampered standardized evaluation of new treatments and, in the case of pharmacological agents, has been an obstacle to FDA approval of medications targeting cognitive deficits in schizophrenia. A fundamental step in developing such a battery was to identify the major separable cognitive impairments in schizophrenia. As part of this effort, we evaluated the empirical evidence for cognitive performance dimensions in schizophrenia, emphasizing factor analytic studies. We concluded that seven separable cognitive factors were replicable across studies and represent fundamental dimensions of cognitive deficit in schizophrenia: Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning and Memory, Visual Learning and Memory, Reasoning and Problem Solving, and Verbal Comprehension. An eighth domain, Social Cognition, was added due to recent increased interest in this area and other evidence of its relevance for clinical trials aiming to evaluate the impact of potential cognitive enhancers on cognitive performance and functional outcome. Verbal Comprehension was not considered appropriate for a cognitive battery intended to be sensitive to cognitive change, due to its resistance to change. The remaining seven domains were recommended for inclusion in the MATRICS-NIMH consensus cognitive battery and will serve as the basic structure for that battery. These separable cognitive dimensions also have broader relevance to future research aimed at understanding the nature and structure of core cognitive deficits in schizophrenia.

Entities:  

Mesh:

Year:  2004        PMID: 15531405     DOI: 10.1016/j.schres.2004.09.007

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  369 in total

1.  Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophrenia.

Authors:  Derek L Jacklin; Amit Goel; Kyle J Clementino; Alexander W M Hall; John C Talpos; Boyer D Winters
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis.

Authors:  Larry J Seidman; Anthony J Giuliano; Eric C Meyer; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Bruce K Christensen; Keith Hawkins; Robert Heaton; Richard S E Keefe; Robert Heinssen; Barbara A Cornblatt
Journal:  Arch Gen Psychiatry       Date:  2010-06

3.  Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.

Authors:  Kathleen S Alexander; Hui-Qiu Wu; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2011-10-26       Impact factor: 4.530

4.  Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods.

Authors:  Nikie Korver; Piotr J Quee; Heleen B M Boos; Claudia J P Simons; Lieuwe de Haan
Journal:  Int J Methods Psychiatr Res       Date:  2012-03-15       Impact factor: 4.035

5.  Comparative effects of different test day challenges on performance in the 5-choice serial reaction time task.

Authors:  Nurith Amitai; Athina Markou
Journal:  Behav Neurosci       Date:  2011-10       Impact factor: 1.912

Review 6.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

7.  Deficient maturation of aspects of attention and executive functions in early onset schizophrenia.

Authors:  Jens Richardt M Jepsen; Birgitte Fagerlund; Anne Katrine Pagsberg; Anne Marie R Christensen; Merete Nordentoft; Erik L Mortensen
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-08-01       Impact factor: 4.785

8.  Nonsocial and social cognition in schizophrenia: current evidence and future directions.

Authors:  Michael F Green; William P Horan; Junghee Lee
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

Review 9.  CNTRICS final task selection: control of attention.

Authors:  Keith H Nuechterlein; Steven J Luck; Cindy Lustig; Martin Sarter
Journal:  Schizophr Bull       Date:  2009-01       Impact factor: 9.306

Review 10.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.